myeloma


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to myeloma: multiple myeloma

my·e·lo·ma

 (mī′ə-lō′mə)
n. pl. my·e·lo·mas or my·e·lo·ma·ta (-mə-tə)
A malignant tumor formed by the cells of the bone marrow.

my′e·lo′ma·toid′ (-toid′) adj.

myeloma

(ˌmaɪɪˈləʊmə)
n, pl -mas or -mata (-mətə)
(Pathology) a usually malignant tumour of the bone marrow or composed of cells normally found in bone marrow
ˌmyeˈlomaˌtoid adj

my•e•lo•ma

(ˌmaɪ əˈloʊ mə)

n., pl. -mas, -ma•ta (-mə tə)
a tumor of plasma cells, arising in bone marrow and often occurring at multiple sites.
[1855–60]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.myeloma - a tumor of the bone marrow (usually malignant) composed of cells normally found in bone marrow
malignant neoplasm, malignant tumor, metastatic tumor - a tumor that is malignant and tends to spread to other parts of the body
multiple myeloma - myeloma that develops in several places at the same time
Translations

my·e·lo·ma

n. mieloma.
1. cualquier tumor de la médula espinal u ósea;
2. tumor formado por el tipo de células que se encuentran en la médula ósea;
multiple ______ múltiple.

myeloma

n mieloma m; multiple — mieloma múltiple
References in periodicals archive ?
ENPNewswire-August 23, 2019--Genmab Announces Approval of DARZALEX in Frontline Multiple Myeloma in Japan
Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leukemia and lymphoma.
Target: Myeloma and Bone Cancer Research rights to the intellectual property for diagnostic testing of patients with myeloma and bone cancer
FDA has placed a partial clinical hold on all clinical trials evaluating venetoclax for the investigational treatment of multiple myeloma. The partial clinical hold follows a review of data from the ongoing Phase 3 BELLINI trial, a study in relapsed/refractory multiple myeloma, in which a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
21, 2019 (HealthDay News) -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say.
Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.
-- (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.
Global Banking News-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
M2 PHARMA-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
M2 EQUITYBITES-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
* REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant
Some University of Arkansas for Medical Sciences employees saw red flags long before auditors discovered a deficit at the Myeloma Institute for Research & Therapy that was allowed to grow to $29 million over nine years.